Is microRNA-31 a key regulator of breast tumorigenesis?

Powrózek, Tomasz; Małecka‐Massalska, Teresa

doi:10.21037/jtd.2017.12.133

Cited by 3 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, miR-31 expression correlated with ER and PR expression but not with HER-2) expression (28). In our study, the association between extensive spread to axillary lymph nodes and low miR-31 expression could be explained considering miR-31 a critical regulator of BC metastasis through promoting cell invasiveness and aggressive BC (31). Other processes mediated by this miRNA have also been identified.…”

Section: Figure 3 Kaplan-meier Survival Curves In Patients With Breas...supporting

confidence: 46%

Role of MicroRNA-31 (miR-31) in Breast Carcinoma Diagnosis and Prognosis

Gharib¹,

Khalifa²,

Eed³

et al. 2022

In Vivo

View full text Add to dashboard Cite

Background/Aim: Breast cancer (BC) is among the most widespread malignant tumors in women. In the current study, we evaluated the role of miR-31 in BC patients and its relation to the different prognostic, clinical, and pathological features. Patients and Methods: MiR-31 levels were determined by RT-PCR in BC and adjacent normal breast tissues from 100 BC patients. BC diagnosis was established through histopathological examinations. The expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) receptor in all tumors was determined using immunohistochemistry. Results: MiR-31 expression was reduced in BC tissues relative to adjacent healthy breast tissue (mean levels were 0.93 and 7.2, respectively). Also, the low expression of miR-31 in BC patients was significantly correlated with adverse clinical and pathological features such as: young patient's age, premenopausal status, infiltrative lobular carcinoma, ER and PR negative tumors, HER2 positive tumors, and advanced clinical stage. Conclusion: MiR-31 was expressed at low levels in BC tissues and correlated with adverse clinical and pathological features, and poor survival.

show abstract

Section: Figure 3 Kaplan-meier Survival Curves In Patients With Breas...supporting

confidence: 46%

Role of MicroRNA-31 (miR-31) in Breast Carcinoma Diagnosis and Prognosis

Gharib¹,

Khalifa²,

Eed³

et al. 2022

In Vivo

View full text Add to dashboard Cite

show abstract

“…MiRNA-31 has been reported to have a role in mammary stem cell (MSC) activity regulation which is controlled by the Notch and Wnt pathways. Many studies have found that this miRNA regulates invasiveness and metastasis formation through activation of several oncogenic genes [20]. In triple-negative breast cancer cells, downregulated expression of miRNA-31 decreased levels of p65, downregulating protein kinase C episilon (PKCε) protein which participates in the regulation of BCL2 protein NF-κB pathway leading to chemosensitivity and apoptosis of tumor cells.…”

Section: Discussionmentioning

confidence: 99%

Using MicroRNA expression levels to detect doxorubicin resistance in breast cancer: A systematic review

Klein,

Posch,

Gandhi

2022

Int. J. Oncol. Res.

View full text Add to dashboard Cite

Aberrant expression of miRNA in tumor cells have been studied for almost a decade for their association with survival. This systematic review summarizes the miRNAs found to have increased expression in doxorubicin-resistant breast cancer cells, their roles in cell survival, and clinical utility of creating a miRNA panel to detect doxorubicin-resistance. Methods: A search in PubMed and Google Scholar was performed to identify studies published until July 2021 on miRNAs associated with doxorubicin-resistance in breast cancer cells. Articles selected for inclusion were evaluated for risk of bias and assessed for quality by using MOOSE guidelines. The identified miRNAs and their roles in cell survival were summarized. Results: A total of 8 studies were included in this systematic review. Most of the studies were primary research of miRNAs associated with doxorubicin-resistance as well as the function of the gene products they produce and their role in chemoresistance. Six different miRNAs with increased expression in doxorubicin-resistant cells relative to parental breast cancer cells were described in more than one study. Conclusion:This systematic review is limited by lack of homogeneity between the included studies owing to sparse data on the subject. Because of the multifactorial process of chemoresistance, several variables and their individual effects on miRNA expression levels are not accounted for consistently across studies due to limited data. More studies are needed to substantiate the increasing evidence that these miRNAs can characterize a chemoresistant phenotype. In the future, the identification of miRNA expression levels in chemoresistant cancer cells can aid in directing therapies to combat their respective mechanism of resistance.

show abstract

Tumor Microenvironment and Epigenetic Implications in Breast Cancer Progression

Darbandi,

Bado

2024

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Is microRNA-31 a key regulator of breast tumorigenesis?

Cited by 3 publications

References 13 publications

Role of MicroRNA-31 (miR-31) in Breast Carcinoma Diagnosis and Prognosis

Role of MicroRNA-31 (miR-31) in Breast Carcinoma Diagnosis and Prognosis

Using MicroRNA expression levels to detect doxorubicin resistance in breast cancer: A systematic review

Tumor Microenvironment and Epigenetic Implications in Breast Cancer Progression

Contact Info

Product

Resources

About